{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029355","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.593564+00:00","generated_at":"2026-06-05T06:13:04.640228+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M","bullets":["Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.","Full-year 2023 net revenue expected $20.7-21.2M.","Audited Q4 and full-year results expected on or about March 26, 2024.","PEDMARK is first FDA-approved therapy to reduce ototoxicity risk in pediatric cisplatin patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029355","json":"https://secwatch.observer/filing/0001104659-24-029355.json","markdown":"https://secwatch.observer/filing/0001104659-24-029355.md","text":"https://secwatch.observer/filing/0001104659-24-029355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/0001104659-24-029355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/tm247601d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:13:04.640228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}